Answer
Yes, hand–foot syndrome (palmar-plantar erythrodysaesthesia) was among the most common adverse reactions reported with sunitinib in RCC, GIST and pNET registrational trials, and symptoms may diminish as treatment continues.
Sources for this answer
- Sunitinib 12.5mg Hard CapsulesTeva UK Limited · emc · SmPC §4.8 Undesirable effects · Version 3Document updated
Sources checked